Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Egyptian International Pharmaceutical Investments (CAI:PHAR) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Egyptian International Pharmaceutical Investments's Enterprise Value for the quarter that ended in Jun. 2026 was E£24,560 Mil.
Egyptian International Pharmaceutical Investments's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was E£2,288 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Egyptian International Pharmaceutical Investments EV-to-EBIT Related Terms
Egyptian International Pharmaceutical Investments EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Egyptian International Pharmaceutical Investments EV-to-EBIT Chart
Egyptian International Pharmaceutical Investments Annual Data
CAI:PHAR vs ZTS, UTHR, VTRS: EV-to-EBIT Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Egyptian International Pharmaceutical Investments's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Egyptian International Pharmaceutical Investments EV-to-EBIT vs Drug Manufacturers Industry
Egyptian International Pharmaceutical Investments's current Enterprise Value is E£31,278 Mil.
Egyptian International Pharmaceutical Investments's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was E£2,288 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Egyptian International Pharmaceutical Investments (CAI:PHAR) has a EV-to-EBIT of 13.67 as of Sep. 09, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Egyptian International Pharmaceutical Investments and its competitors. This is 104% above median its historical median of 6.69. Over the past decade, Egyptian International Pharmaceutical Investments' EV-to-EBIT has ranged from 2.02 to 13.86. According to the industry distribution chart, Egyptian International Pharmaceutical Investments ranks #304 out of 682 companies in the Drug Manufacturers industry, placing it in the top 44.6%.
Is Egyptian International Pharmaceutical Investments' EV-to-EBIT too high?
Egyptian International Pharmaceutical Investments' current EV-to-EBIT of 13.67 is 104% above median its 10-year median of 6.69. Over the past 10 years, this metric has ranged from a low of 2.02 to a high of 13.86. The Drug Manufacturers industry median EV-to-EBIT is 16.11. Egyptian International Pharmaceutical Investments' value of 13.67 is 15.1% below this industry median. Based on the distribution chart, Egyptian International Pharmaceutical Investments ranks #304 out of 682 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Egyptian International Pharmaceutical Investments has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Egyptian International Pharmaceutical Investments' EV-to-EBIT compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Egyptian International Pharmaceutical Investments ranks #304 out of 682 companies for EV-to-EBIT. This puts Egyptian International Pharmaceutical Investments in the upper half of its industry. The industry median EV-to-EBIT is 16.11. Egyptian International Pharmaceutical Investments' value of 13.67 is 15.1% below this benchmark. Historically, Egyptian International Pharmaceutical Investments' own EV-to-EBIT has ranged from 2.02 to 13.86 over the past decade. While the company's 10-year median is 6.69 vs. the industry median of 16.11, Egyptian International Pharmaceutical Investments has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 16.11, based on 682 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Egyptian International Pharmaceutical Investments's current EV-to-EBIT of 13.67 is 15.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Egyptian International Pharmaceutical Investments and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 16.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Egyptian International Pharmaceutical Investments's current EV-to-EBIT is 13.67, which is 104% above median its own 10-year median of 6.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Egyptian International Pharmaceutical Investments stock overvalued right now?
Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments (CAI:PHAR) is currently considered Significantly Overvalued. The stock's GF Value™ is E£60.89, compared to a current price of E£127.20 — trading 108.9% above its estimated fair value. The current EV-to-EBIT is 13.67, which is 104% above median its 10-year median of 6.69 and 15.1% below the Drug Manufacturers industry median of 16.11. Egyptian International Pharmaceutical Investments' overall GF Score™ is 67/100 with 15 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Egyptian International Pharmaceutical Investments (CAI:PHAR), the current EV-to-EBIT is 13.67 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Egyptian International Pharmaceutical Investments (CAI:PHAR) Overvalued in 2026?
Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments stock appears to be overvalued.
The current stock price of E£127.20 is trading 108.9% above its estimated GF Value™ of E£60.89.
GuruFocus considers Egyptian International Pharmaceutical Investments to be Significantly Overvalued.
Key valuation signals for CAI:PHAR:
EV-to-EBIT: 13.67 (104% above median its 10-year median of 6.69)
GF Value™: E£60.89 vs. price of E£127.20 (108.9% above fair value)
Industry Position: 15.1% below the Drug Manufacturers median (#304 of 682)
No single metric tells the full story. See the CAI:PHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Egyptian International Pharmaceutical Investments is an Egypt based company pharmaceutical generic drugs. It holds license agreements with a group of pharmaceutical companies to produce their products locally and replace the imported ones. The company produces dosage forms, Spansule capsules, Antibiotics, Lyophilized Products. It exports its products to African, Asian and East European and Latin American Countries.
67GF Score
Get the complete analysis for CAI:PHAR
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:PHAR has been successfully added to your 
